Skip to content
Menu

Acadia Pharmaceuticals Inc. ACAD

Full chart Compare
Set alert

Price alert · ACAD

All alert types
17.67 USD +0.08 (+0.45%)

As ofNov 20, 2026, 11:15 AM EST

17.42 Day range 17.79
15.86 52-week range 30.96
YTD
-33.85%
1 year
-22.84%

5D -1.30 (-6.87%)

1819MonTueWedThuFri17.63
Market cap
3.06B
Revenue (ttm)
1.20B
Profit margin
30.13%
EPS (ttm)
2.12
Shares out
172.83M
P/E ratio
8.34
Forward P/E
16.19
YTD return
-33.85%
1-year return
-22.84%
50-day average
21.22
Volume
442.46K
Avg volume
2.17M
Open
17.47
Previous close
17.59
Day's range
17.42 – 17.79
52-week range
15.86 – 30.96
Beta
0.89
Analysts
Buy
Price target
30.21 (+71.0%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
23.23
Enterprise value
2.18B
PEG ratio
50.86
Price / sales
2.53
Price / book
2.19
Revenue growth
22.80%
Free cash flow
46.27M
Total cash
976.45M
Total debt
71.85M
Return on equity
31.43%
Short % of float
7.59%

Fundamental scorecard

15 of 25 checks passed on ACAD’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 3 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ACAD Revenue — quarterly 342.29M
ACAD Net income — quarterly 53.52M
ACAD EPS — quarterly 0.31

Earnings

ACAD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20260.28———
Nov 4, 2026Sep 30, 20260.19920.31+0.11+55.62%
Aug 4, 2026Jun 30, 20260.068150.18+0.11+164.12%
May 6, 2026Mar 31, 20260.040.02-0.02-50.00%
Feb 25, 2026Dec 31, 20250.1371.60+1.46+1,067.88%
Nov 5, 2025Sep 30, 20250.140.42+0.28+200.00%

Upgrades / downgrades

ACAD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Canaccord GenuitymainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Oct 19, 2026NeedhamreitBuyBuy
Oct 13, 2026UBSdownBuyNeutral
Oct 8, 2026RBC CapitalmainOutperformOutperform
Sep 25, 2026Deutsche BankmainBuyBuy

About Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
acadia.com

News

Your note

Sign in to keep a note on ACAD — it syncs with the Stock Master app.

Insider holders

ACAD insider holders
InsiderRelationLatest transactionDateShares held
ADAMS CATHERINE OWENChief Executive OfficerSaleMar 24, 202614,803
BAKER BROS ADVISORS L.P.Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)May 28, 20260
BAKER BROTHERS LIFE SCIENCES L PDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)May 28, 20250
BREGE LAURA ADirectorConversion of Exercise of derivative securityMay 28, 202623,202
GAROFALO ELIZABETH AMY M.D.DirectorConversion of Exercise of derivative securityMay 28, 202633,489
HARRIGAN EDMUND P. M.D.DirectorConversion of Exercise of derivative securityMay 28, 202643,148

Institution ownership

ACAD institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP24.83%42,912,904754.41MSep 29, 2026
Blackrock Inc.13.28%22,947,481403.42MSep 29, 2026
Vanguard Portfolio Management LLC5.47%9,457,124166.26MSep 29, 2026
State Street Corporation4.43%7,650,889134.50MSep 29, 2026
RTW Investments LP4.13%7,144,524125.60MSep 29, 2026
Vanguard Capital Management LLC3.35%5,790,801101.80MSep 29, 2026

Fund ownership

ACAD fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF4.45%7,694,693135.27MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.36%4,074,46571.63MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.93%3,329,82658.54MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.71%2,949,28751.85MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.43%2,472,50243.47MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund0.98%1,699,37729.88MJun 29, 2026